Natco Pharma Q2 Results: Net profit surges 83%, topline and margin expand from last year

Natco Pharma Ltd. reported its September quarter results on Tuesday, November 12, which were higher on a year-on-year basis on all parameters. The growth during the second quarter was driven by a strong performance in exports formulation business and stable domestic pharma business.

The pharma company reported a 83% jump in its net profit at ₹676.5 crore for the September quarter. It had reported a net profit of ₹369 crore during the same period last year.

Revenue for the said quarter also increased by 33% to ₹1,371 crore, compared to ₹1,031 crore in the same period last year.

Natco Pharma's Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) surged 75.7% to ₹804.2, while margin expanded on a year-on-year basis to 58.66% from 44.40% in the year-ago quarter. Its higher gRevlimid flow-through has supported the margins.

The board of the company announced a second interim dividend of ₹1.50 per equity share of face value of ₹2 each for the financial year 2024-25.

Record date for the above mentioned dividend has been fixed as November 25, 2024. The payment of the said interim dividend will be made by December 2, 2024.

Shares of Natco Pharma Ltd. have declined to the lowest point of the day post the earnings announcement. The stock is now trading lower at ₹1,382.10.

Note To Readers

Disclaimer: The views and investment tips expressed by investment experts on CNBCTV18.com are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.